


RESEARCH

Open Access



Prescribing pattern of anti-psychotic medications in patients with dementia in Oman: a retrospective observational study

Zainab Al-Rashdi¹, Tamadhir Al-Mahrouqi^{1*} , Siham Al-Shamli², Sathiya Panchatcharam³, Fatema Al-Busaidi⁴, Reem Al-Afani⁴, Naser Al-Balushi⁵ and Hamed Al-Sinawi⁵

Abstract

Background: Aggression, agitation, psychosis, and sleep disturbances are common behavioral symptoms of people with dementia and they can be distressing for both individuals and their carers. Due to their potential side effects, antipsychotic medications are recommended only for severe behavioral and psychological symptoms of dementia (BPSD). This study explores the prevalence, patterns, and associated factors with antipsychotic drug use among patients with dementia attending geriatric psychiatry services at Sultan Qaboos University Hospital (SQUH). Using a retrospective cross-sectional design, this study examines antipsychotic use among elderly patients aged 60 years or older with dementia who attended geriatric psychiatry services from January 2020 to December 2021. The following information was solicited: socio-demographic factors, type and severity of dementia, presence of co-morbid medical or mental illness, the psychotropic medications prescribed, the anti-psychotic medication use, duration of use, and the indication of use were solicited as well. A multivariate logistic regression analysis was conducted.

Results: The total prevalence of anti-psychotic use among elderly patients with dementia was 56.6%, and among them, 59% were prescribed anti-psychotics for more than 2 years. Being female, having non-Alzheimer's dementia, experiencing severe stages of dementia, and having other medical or mental co-morbid conditions were independent predictors of antipsychotic drug use (odds ratio [OR] = 1.85, confidence interval [CI] = 1.04–3.30; OR = 2.77, C.I. 1.52–5.04; OR = 4.47, C.I. 2.18–9.18; and OR = 2.54, C.I. 1.11–5.78, respectively).

Conclusions: Antipsychotic medication use is prevalent among elderly patients with dementia in Oman. The results from this study will help the policymakers and psychiatrists in Oman to plan for the use of non-pharmacological strategies as the first line of management for BPSD.

Keywords: Antipsychotics, Dementia, Behavioral symptoms, Neuropsychiatric Symptoms, Oman

Background

During the course of dementia, many patients exhibit non-cognitive symptoms and behaviors which are referred to as neuropsychiatric symptoms or behavioral and psychological symptoms of dementia (BPSD), such

as aggression, agitation, psychosis, sleep disturbance, appetite changes, and others [1]. Among patients diagnosed with dementia, more than 90% develop at least 1 of these symptoms during their illness [2].

BPSD is distressful for patients and caregivers as well, therefore to improve the quality of life for both patient and caregiver, BPSD should be targeted during the treatment of Dementia. Behavioral management is recommended to be the first line in treating BPSD, but it may not be effective in severe cases. If the non-pharmacological approach fails then antipsychotics can be used,

*Correspondence: tamadhirmahrouqi@gmail.com

¹ Psychiatry Residency Training Program, Oman Medical Speciality Board, Muscat, Oman

Full list of author information is available at the end of the article

which are usually reserved for severe cases. However, antipsychotic use among the elderly increases the risk of cerebrovascular adverse events, cognitive decline, parkinsonism, gait disturbance, sedation, and pneumonia [3].

Previous studies have demonstrated a clear association between treatment with antipsychotic medications and increased morbidity and mortality in people with dementia [4]. Therefore, the use of antipsychotics is often limited by their side effects profile [5]. Because of the increased risk of cerebrovascular adverse effects, the National Institute for Health and Clinical Excellence (NICE) guideline, recommended that antipsychotic drugs should not be prescribed for patients whose non-cognitive symptoms were of mild-moderate severity [5]. Previous international studies have addressed the pattern of antipsychotic prescriptions in dementia patients. Many studies indicate that around 32% of patients with dementia received antipsychotics [6, 7]. A systemic review conducted in 2016, including 16 meta-analysis studies to evaluate the use of antipsychotics in patients with dementia, concluded that antipsychotics showed modest efficacy in treating psychosis, agitation, and aggression in patients with dementia [3].

Available data indicates that in patients with Alzheimer's disease (AD): olanzapine, risperidone, and aripiprazole showed modest benefits in the management of psychosis and aggression over a period of 6–12 weeks [8]. However, quetiapine didn't show a similar benefit. In addition, there is limited evidence available for the use of antipsychotic medications in individuals with non-Alzheimer's dementia type [9].

According to numerous studies, antipsychotics are frequently prescribed for dementia patients with limited monitoring of their side effects, and they are often prescribed for lengthy periods (more than 6 months). On the other hand, the benefits of antipsychotic treatment for dementia patients over longer periods are still unknown [8–12].

There is a lack of knowledge about the patterns of antipsychotic prescription in middle eastern communities. In light of this, a study was done to determine the prevalence and patterns associated with antipsychotic use and to establish a set of recommendations for the administration of antipsychotics to dementia patients as well as for their monitoring.

Methods

Study design and setting

This was a retrospective cross-sectional study conducted by extracting 24 months of data from the electronic medical records of elderly patients (age more than or equal to 60 years) diagnosed with a major neurocognitive disorder based on the Diagnostic and Statistical Manual of

Mental Disorders fifth edition criteria (DSM-5) [13] who are attending in-patient and/or out-patient geriatric psychiatry services at Sultan Qaboos University Hospital (SQUH), a tertiary referral hospital located in Muscat, the capital city and is providing specialist mental health care services.

Study sample and sampling method

We included all elderly patients (age ≥ 60 years) attending in-patient and or out-patient geriatric psychiatry services at SQUH who met the DSM-5 criteria [13] for the major neurocognitive disorder during the study period. The study sample was recruited using a systemic random sampling (every second patient) approach. Any recruited participant who failed to meet the inclusion criteria was excluded from the study and replaced with the next potential participant.

Inclusion and exclusion criteria of the study participants

We included elderly patients (age ≥ 60 years), who were diagnosed with a major neurocognitive disorder based on the DSM-5 criteria [13] during the period from January 2020 to December 2021. We excluded patients whose clinical records had missing data, we tried to compensate by collecting the missing data from the treating psychiatrist, and when this is not possible the patient is excluded.

Data source and collection

Data were extracted from patients' electronic medical records from January 2020 to December 2021 through the hospital information system department after obtaining ethical approval from Sultan Qaboos University Hospital Research and Ethics Committee (MREC2636). The research protocols and procedures conformed to the guidance of the World Medical Association's Declaration of Helsinki for ethical human research.

Outcome measures

The data extracted from patients' medical records were classified into (1) socio-demographic factors, following information solicited age, gender, marital status, educational level, and region of residence; (2) type and severity of dementia. The type of dementia was classified based on DSM-5 criteria [13] and the severity of dementia was classified into mild, moderate, and severe, based on the dementia classification in the Rockwood Clinical Frailty Scale [14]; (3) presence of co-morbid medical or mental illness based on DSM-5 criteria [13]; (4) The prescribed anti-psychotic, and anti-dementia medications; (5) the anti-psychotic medication name, duration of use was solicited as well.

Rockwood Clinical Frailty Scale

A frailty assessment tool is useful for assessing individuals with cognitive impairment. These are helpful in guiding decisions about treatment plans, and there are several scales that can be applied, but a straightforward instrument like the Rockwood Clinical Frailty Scale can be a quick method for assessing individuals who have cognitive impairment. It requires the clinician to observe the patient mobilizing and inquire about their routine physical activity and capacity for self-care. The level of frailty is correlated with the degree of dementia [15]. It has three dementia classifications: mild, moderate, and severe. Individuals with mild frailty are correlated with mild dementia, those individuals forget details of recent events, though they still remember the event itself, repeat the same question/story, and experience social withdrawal. Individuals with moderate dementia, have very impaired recent memory, even though they seemingly can remember their past life events well. As with moderate frailty, they can do personal care with prompting. Individuals with severe dementia, as in severe frailty, cannot perform personal care without help. The scale has moderate to good inter-rater reliability [16] and is a validated diagnostic tool to assess frailty in elderly hospital patients and patients in the emergency room [17].

Co-morbid medical or mental conditions

The co-morbid medical or mental conditions were measured by the presence of at least one medical or mental illness. The participant's medical records were reviewed for whether they had one or more medical or mental co-morbid conditions, for example, respiratory disorders (such as obstructive sleep apnea, asthma), cardiovascular disorders (for example dyslipidemia, coronary acute syndrome, hypertension), endocrine disorders (for example diabetes, thyroid dysfunction), hematological disorders (for example, iron deficiency anemia), and neurological disorders (for example, stroke). For mental conditions, we reviewed the medical records and documented co-morbid mental illnesses which were diagnosed based on the DSM-5 criteria [13], for example, affective and anxiety disorders.

Statistical analysis

Collected data were analyzed using IBM SPSS Statistics 27.0 (IBM Corp. Released 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp). For descriptive purposes, continuous variables were presented with mean with standard deviation, and categorical variables were presented with frequency and percentages. The chi-square test was used for comparison between groups; multivariate logistic regression analysis

was done using enter method, considering the significant factors from univariate and close to the significant factors (up to 0.2 level). A p -value of < 0.05 was taken as statistical significance.

Results

Table 1 shows the demographics and clinical variables distribution, there were 251 patients diagnosed with dementia with a mean age of 74.43 ± 8.62 years, 57% of the cases were women, 70.5% were married and about 23% were widows/widowers. The majority of the cases 58% were from outside of the capital of Oman. About 46% were experiencing a severe stage of dementia and 28% were in the moderate or mild stage of dementia. A total of 56.6% were prescribed anti-psychotics, among them, 59% of them used the anti-psychotics for more than 2 years. Besides anti-psychotics, 67.3% of patients were prescribed cholinesterase inhibitor drugs (chEI).

Table 2 shows the association between demographic, clinical variables, and anti-psychotic use. The following factors were entered into the model, gender, Alzheimer's status, severity, use of anti-dementia medications, and the presence of comorbid medical conditions. After adjusting for these factors in the model, the following factors remain independent predictors for the use of antipsychotics. The female gender showed higher use compared to the male gender (OR=1.85; 95% C.I. 1.04–3.30, $p=0.038$), non-Alzheimer's dementia (OR=2.77; 95% C.I. 1.52–5.04, $P=0.001$). Patients with severe dementia stages were likely to use more medications, and those who had comorbid medical or mental conditions showed statistically significant results (OR=4.47, 95% C.I. 2.18–9.18, $P=0.001$ and OR=2.54, 95% C.I. 1.11–5.78, $p=0.027$, respectively).

Discussion

Numerous research looked into how anti-psychotics were prescribed to dementia patients in western societies. And to the best of our knowledge, this is the first investigation into the antipsychotic prescribing patterns among dementia patients in Oman and the Arabian Peninsula.

This study revealed that 56% of patients diagnosed with dementia were prescribed antipsychotics for BPSD, this prevalence is significantly higher compared to that reported in Japan at a prevalence of 10.7% [18], and in the USA at a prevalence of 14.9% [19]. Moreover, in a recent study conducted among patients with dementia during the COVID-19 pandemic in England showed a prevalence around of 9% [20] Compared to the worldwide prevalence, our study population had a high rate of antipsychotic prescriptions. This could be explained by the following factors: first, our study was conducted at the geriatric psychiatry services at SQUH, a tertiary care

Table 1 Patients' demographic and clinical variables distribution

Variables	n (%)
Age group	
60–65 years	38 (15.1)
66–75 years	103 (41.0)
76–85 years	83 (33.1)
> 85 years	27 (10.8)
Age during prescribing anti-psychotic (mean±sd)	74.43±8.62
Gender	
Male	108 (43.0)
Female	143 (57.0)
Marital status	
Single	3 (1.2)
Married	177 (70.5)
Divorced	13 (5.2)
Widow/widower	58 (23.1)
Region	
Muscat	106 (42.2)
Outside Muscat	145 (57.8)
Educational level	
Illiterate	22 (8.8)
High school graduate	4 (1.6)
High school diploma	13 (5.2)
Bachelor's degree	6 (2.4)
Unknown	206 (82.1)
Severity of dementia	
Mild stage	64 (25.5)
Moderate stage	71 (28.3)
Severe stage	116 (46.2)
Duration of anti-psychotic use	
No anti-psychotic prescribed	109 (43.4)
Anti-psychotic prescribed	142 (56.6)
<1 year	21 (8.4)
1–2 years	32 (12.7)
>2 years	77 (30.7)
Unknown duration	12 (4.8)
Anti-dementia agents used, besides anti-psychotic	
ChEI	169 (67.3)
ChEI + NMDA antagonist	10 (4.0)
NMDA antagonist	11 (4.4)
No anti-dementia agent used	61 (24.3)

ChEI cholinesterase inhibitor drugs, NMDA antagonist N-methyl-D-aspartate receptor antagonists

hospital, receiving referrals from other primary and secondary care hospitals for severe and complex cases needing specialized management. Second, our facility has almost no resources for alternative non-pharmacological strategies for BPSD management.

Our study found that antipsychotic medications were prescribed more frequently for dementias other than

Alzheimer's. Despite the scant evidence supporting the effectiveness of antipsychotic medications in this population and their potential for harm. The higher prevalence of behavioral symptoms and psychosis in non-Alzheimer's dementia could be a possible explanation. This finding is consistent with that of a sizable US database study, which found that individuals with Parkinson's disease and dementia received antipsychotic medications much more frequently than those with other types of dementia [21]. Moreover, results from our study revealed that patients with severe dementia were more frequently prescribed antipsychotics compared to patients with mild dementia. This finding is consistent with results from a systemic review and a meta-analysis showing an increasing prevalence of antipsychotic use with increasing severity of dementia the results revealed that in studies with moderate dementia, the prevalence of antipsychotic use was 12.2%, and in studies with severe dementia, the prevalence was 45.1% [22].

In our study, women were more likely than men to receive an antipsychotic prescription; nevertheless, the relationship between antipsychotic use and gender is still controversial, with some studies reporting that women received antipsychotic prescriptions more frequently than men [23, 24]. Contrary to several other studies' findings suggesting that men are more likely to receive antipsychotic prescriptions compared to women [25, 26].

This study showed that there was a greater incidence of antipsychotic prescription when there was co-morbid medical and mental illness. However, a number of recent studies revealed that antipsychotics were less frequently prescribed to dementia patients who had a history of cardiovascular or cerebrovascular conditions such as hypertension, diabetes, stroke, and renal/hepatic dysfunction [27]. Antipsychotics should only be prescribed to individuals with cardiovascular or cerebrovascular illnesses who are extremely distressed and for brief periods of time [5]. Our findings, therefore, indicate that this older population with co-morbid medical and mental illness should be given more attention in the assessment of these individuals' risks and benefits against the antipsychotic prescription.

The results revealed that antipsychotics were used for more than 2 years in most of the cases 30%, and in only 8% of cases antipsychotics were used for less than 1 year. The duration of antipsychotic prescription observed in our study is inconsistent with that found in the UK mental health services [9]. Moreover, the advantages of using antipsychotics for BPSD treatment for longer than 12 weeks are still unknown. Therefore, it is advised to regularly and frequently reevaluate patients to determine whether they still require anti-psychotic treatment [9].

Table 2 Association between demographic, clinical variables, and anti-psychotic use

Variables	Unadjusted analysis			Adjusted analysis	
	No (n=109)	Yes (n=130)	p-value	OR (95% CI)	p-value
Age group					
60–65 years	19 (17.4)	18 (13.8)	0.628		
66–75 years	42 (38.5)	58 (44.6)			
76–85 years	35 (32.1)	43 (33.1)			
> 85 years	13 (11.9)	11 (8.5)			
Gender					
Male	51 (46.8)	49 (37.7)	0.188	1.0	
Female	58 (53.2)	81 (62.3)		1.85 (1.04–3.30)	0.038
Marital status					
Married	80 (74.8)	89 (69.0)	0.612		
Divorced	5 (4.7)	8 (6.2)			
Widow/widower	22 (20.6)	32 (24.8)			
Dementia type					
Alzheimer's	80 (74.1)	66 (52.0)	<0.001		
LBD*	5 (4.6)	9 (7.1)			
Mixed dementia	9 (8.3)	24 (18.9)			
Vascular dementia	14 (13.0)	17 (13.4)			
Others	-	11 (8.7)			
Alzheimer's dementia					
Non-Alzheimer's Dementia	80 (74.1)	66 (52.0)	<0.001	1.0	
	28 (25.9)	61 (48.0)		2.77 (1.52–5.04)	<0.001
Severity of dementia					
Mild stage	38 (34.9)	21 (16.2)	<0.001	1.0	
Moderate stage	34 (31.2)	33 (25.4)		2.01 (0.93–4.37)	0.076
Severe stage	37 (33.9)	76 (58.5)		4.47 (2.18–9.18)	<0.001
Use of Anti-dementia					
No	98 (89.9)	104 (80.0)	0.047		
Yes	11 (10.1)	26 (20.0)			
Comorbid medical or mental conditions					
No	98 (89.9)	104 (80.0)	0.047	1.0	
Yes	11 (10.1)	26 (20.0)		2.54 (1.11–5.78)	0.027

LBD Lewy body dementia

Limitation

Data were extracted from the patient's clinical records; therefore, some errors are expected in data collection. However, we tried to compensate for this by asking the treating psychiatrist for any unclear documented information. Moreover, our study was conducted at a tertiary care hospital, where severe cases are seen, this might have affected the generalizability of our results.

Conclusions

Identifying the factors that increase the likelihood of antipsychotic prescription may help to consider alternatives to antipsychotic medications at earlier stages of

dementia disease. Psychiatrists are advised to use non-pharmacological strategies as a first line in managing BPSD. When nonpharmacologic methods are not effective in treating distressing symptoms then psychiatrists are advised to use anti-psychotic medications, provided that they document in patient clinical notes the indication and the target symptoms for initiating the antipsychotic medication. Moreover, psychiatrists are recommended to perform clinical re-assessment and medications review at least every 6 months, to consider withdrawing the anti-psychotics depending on the clinical assessment. Future studies in Oman could also examine and report polypharmacy, drug-to-drug interactions, and any adverse consequences of antipsychotic

treatment in dementia patients. Future studies may also examine the effectiveness of other alternative treatments to antipsychotic medications. Probably, by assessing dementia patients' quality of life while using non-pharmacological methods and contrasting it with the use of antipsychotic medications.

Abbreviations

BPSD: Behavioral and psychological symptoms of dementia; chEI: Cholinesterase inhibitor drugs; CI: Confidence interval; DSM-5: Diagnostic and Statistical Manual of Mental Disorders Fifth Edition; LBD: Lewy body dementia; NICE: National Institute for Health and Clinical Excellence; NMDA: N-Methyl-D-aspartate receptor antagonists; OR: Odds ratio; SQUH: Sultan Qaboos University Hospital.

Acknowledgements

Not applicable.

Authors' contributions

ZR, TM, and HS contributed to the research design. FA, RA, and TM collected the data. NB, SP, and ZR analyzed the data. All authors contributed to the manuscript writing. ZR, SS, TM, and HS revised the manuscript. All authors approved the final version of the manuscript.

Funding

No funding was received for this research.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

Ethical approval to conduct this research was granted by Sultan Qaboos University Hospital Research and Ethics Committee (MREC2636). The research protocols and procedures conformed to the guidance of the World Medical Association's Declaration of Helsinki for ethical human research.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

¹Psychiatry Residency Training Program, Oman Medical Speciality Board, Muscat, Oman. ²Ministry of Health, Muscat, Oman. ³Research and Studies Department, Oman Medical Specialty Board, Muscat, Oman. ⁴Medical Internship Training Program, Sultan Qaboos University Hospital, Muscat, Oman. ⁵Behavioural Medicine Department, Sultan Qaboos University Hospital, Muscat, Oman.

Received: 2 November 2022 Accepted: 17 December 2022

Published online: 07 January 2023

References

- Chiu Y, Bero L, Hessel NA, Lexchin J, Harrington C (2015) A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. *Health Policy* 119(6):802–813 Available from: <https://pubmed.ncbi.nlm.nih.gov/25791166/>
- Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C et al (2012) Risk of Mortality Among Individual Antipsychotics in Patients with Dementia. *Am J Psychiatry* 169(1):71 Available from: <file:///pmc/articles/PMC4269551/>
- Tampi RR, Tampi DJ, Balachandran S, Srinivasan S (2016) Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. *Ther Adv Chronic Dis* 7(5):229–245 Available from: <https://pubmed.ncbi.nlm.nih.gov/27583123/>
- Feng Z, Hirdes JP, Smith TF, Finne-Soveri H, Chi I, Du Pasquier JN et al (2009) Use of physical restraints and antipsychotic medications in nursing homes: a cross-national study. *Int J Geriatr Psychiatry* 24(10):1110–1118 Available from: <https://pubmed.ncbi.nlm.nih.gov/19280680/>
- NICE. Dementia: supporting people with dementia and their carers in health and social care [Internet]. Available from: <https://www.nice.org.uk/guidance/cg42>. Accessed 22 Nov 2006
- Kamble P, Chen H, Sherer JT, Aparasu RR (2009) Use of Antipsychotics among Elderly Nursing Home Residents with Dementia in the US. *Drugs Aging* 26(6):483–492 Available from: <https://link.springer.com/article/10.2165/00002512-200926060-00005>
- Foebel AD, Liperoti R, Onder G, Finne-Soveri H, Henrard JC, Lukas A et al (2014) Use of Antipsychotic Drugs Among Residents With Dementia in European Long-Term Care Facilities: Results From the SHELTER Study. *J Am Med Dir Assoc* 15(12):911–917 Available from: <http://www.jamda.com/article/S152586101400471X/fulltext>
- Wetzels RB, Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT (2011) Prescribing pattern of psychotropic drugs in nursing home residents with dementia. *Int Psychogeriatr* 23(8):1249–1259 Available from: <https://pubmed.ncbi.nlm.nih.gov/21682938/>
- Barnes TRE, Banerjee S, Collins N, Treloar A, McIntyre SM, Paton C (2012) Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services. *Br J Psychiatry* 201(3):221–226 Available from: <https://pubmed.ncbi.nlm.nih.gov/22790679/>
- Gustafsson M, Karlsson S, Lövhelm H (2013) Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units. *BMC Pharmacol Toxicol* 14:10 Available from: <file:///pmc/articles/PMC3575309/>
- Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH (2010) Unexplained variation across US nursing homes in antipsychotic prescribing rates. *Arch Intern Med* 170(1):89–95 Available from: <https://pubmed.ncbi.nlm.nih.gov/20065204/>
- Gellad WF, Aspinall SL, Handler SM, Stone RA, Castle N, Semla TP et al (2012) Use of Antipsychotics among Older Residents in Veterans Administration Nursing Homes. *Med Care* 50(11):954 Available from: <file:///pmc/articles/PMC3746977/>
- Association AP. Diagnostic and Statistical Manual of Mental Disorders [Internet]. American Psychiatric Association; 2013. Available from: <https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596>. Accessed 18 May 2013
- Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I et al (2005) A global clinical measure of fitness and frailty in elderly people. *CMAJ* 173(5):489–495 Available from: <https://pubmed.ncbi.nlm.nih.gov/16129869/>
- Rockwood K, Theou O (2020) Using the Clinical Frailty Scale in Allocating Scarce Health Care Resources. *Can Geriatr J* 23(3):254–259 Available from: <https://pubmed.ncbi.nlm.nih.gov/32904824/>
- Hörlin E, Munir Ehlrlington S, Henricson J, John RT, Wilhelms D (2022) Inter-rater reliability of the Clinical Frailty Scale by staff members in a Swedish emergency department setting. *Acad Emerg Med* Available from: <https://pubmed.ncbi.nlm.nih.gov/36200372/>. Accessed 6 Oct 2022
- Stille K, Temmel N, Hepp J, Herget-Rosenthal S (2020) Validation of the Clinical Frailty Scale for retrospective use in acute care. *Eur Geriatr Med* 11(6):1009–1015 Available from: <https://pubmed.ncbi.nlm.nih.gov/32770462/>
- Kuroda N, Hamada S, Sakata N, Jeon B, Iijima K, Yoshie S et al (2019) Antipsychotic use and related factors among people with dementia aged 75 years or older in Japan: A comprehensive population-based estimation using medical and long-term care data. *Int J Geriatr Psychiatry* 34(3):472–479 Available from: <https://pubmed.ncbi.nlm.nih.gov/30478985/>
- Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio R et al (2011) Trends in antipsychotic use in dementia 1999–2007. *Arch Gen Psychiatry* 68(2):190–197 Available from: <https://pubmed.ncbi.nlm.nih.gov/21300946/>

20. Howard R, Burns A, Schneider L (2020) Antipsychotic prescribing to people with dementia during COVID-19. *Lancet Neurol* 19(11):892 Available from: <file:///pmc/articles/PMC7577650/>
21. Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC (2011) Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. *Arch Neurol* 68(7):899–904 Available from: <https://pubmed.ncbi.nlm.nih.gov/21747029/>
22. Kirkham J, Sherman C, Velkers C, Maxwell C, Gill S, Rochon P et al (2017) Antipsychotic Use in Dementia: Is There a Problem and Are There Solutions? *Can J Psychiatry* 62(3):170 Available from: <file:///pmc/articles/PMC5317021/>
23. Trifirò G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G (2005) Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999–2002. *Eur J Clin Pharmacol* 61(1):47–53 Available from: <https://pubmed.ncbi.nlm.nih.gov/15666172/>
24. Wattmo C, Londos E, Minthon L (2014) Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services. *Clin Interv Aging* 9:1951–1962 Available from: <https://pubmed.ncbi.nlm.nih.gov/25484578/>
25. Tifratene K, Manera V, Fabre R, Gros A, Thummler S, Pradier C et al (2017) Antipsychotic prescribing for Alzheimer's disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study. *Alzheimers Res Ther* 9(1) Available from: <https://pubmed.ncbi.nlm.nih.gov/28446209/>. Accessed 26 Apr 2017
26. Xiong GL, Filshtein T, Beckett LA, Hinton L (2015) Antipsychotic Use in a Diverse Population With Dementia: A Retrospective Review of the National Alzheimer's Coordinating Center Database. *J Neuropsychiatr Clin Neurosci* 27(4):326–332 Available from: <https://pubmed.ncbi.nlm.nih.gov/26488486/>
27. Chiu YW, Huang CW, Chen PJ, Yu NW, Tsai HJ, Wu CS et al (2017) Trends and factors associated with antipsychotic use among elderly patients with dementia in Taiwan from 2005 to 2013: a population-based study. *Int Clin Psychopharmacol* 32(5):262–270 Available from: <https://pubmed.ncbi.nlm.nih.gov/28542035/>

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)
